arrow
X

Xiaozhong Qian

daiichi sankyo company limited
H指数:20
被引数:3,190

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

In vivo efficacy of anti-B7-H3 antibody-drug conjugate (ADC) ifinatamab deruxtecan (I-DXd; DS-7300): An update from the Pediatric Preclinical In Vivo Testing (PIVOT) Program
2024-04-051
PRE
Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study

晚期实体瘤患者的Ifinatamab deruxtecan (i-dxd; DS-7300): I/II期研究的最新临床和生物标志物结果

2023-10-013
PRE
Ifinatamab deruxtecan (I-DXd), a novel B7-H3-targeting antibody-drug conjugate, demonstrates efficient payload delivery into tumor through target-dependent internalization
2023-04-041
PRE
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial

放疗联合nivolumab或替莫唑胺治疗MGMT启动子未甲基化的新诊断胶质母细胞瘤: 一项国际随机III期试验

2022-04-14240
OAAI
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients
2018-03-1550
OAAI
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

小分子组蛋白去乙酰化酶抑制剂的种类和异构体选择性的测定

2007-12-21721
OAAI